Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (323)	4/4/2005 8:11:41 PM
From: Sam Citron	Respond to of 510

Early shorts are normally well compensated, but this one is non-marginable due to low trading price. I'm not speaking of the potential investment merits of this company, but merely the trading pattern lately of biotechs that disappoint. Sam

To: Biomaven who wrote (323)	4/5/2005 3:40:03 PM
From: tuck	Read Replies (1) \| Respond to of 510

That turned out to be an excellent strategy here, Peter. Here is an outstanding summary of the issues surrounding new detection techniques for ovarian cancer, in which Ciphergen is most prominently mentioned. Predictive value in a rare disease, sample handling and scarcity, etc. (thanks to okeah2002 of the YMB for the dig): pharmaceuticaldiscovery.com One bad thing in there: flash freezing seems to be pretty important for sample integrity, and this is apparently not a good option in a high volume clinical lab setting (I did not know the latter until this author pointed it out). Cheers, Tuck